{"id":5653,"date":"2026-10-13T10:47:40","date_gmt":"2026-10-13T05:17:40","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/drreddy-share-price-today-2026-10-13\/"},"modified":"2026-10-13T10:47:42","modified_gmt":"2026-10-13T05:17:42","slug":"drreddy-share-price-today-2026-10-13","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/drreddy-share-price-today-2026-10-13\/","title":{"rendered":"Dr. Reddy S Laboratories Share Price Today: Why DRREDDY Is Rising 2.71% | 13 October 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: DRREDDY<\/strong> \u00b7 13 October 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b91,229.40<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>+2.71%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b91,234.60 \/ \u20b91,224.40<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b91,197.00<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>1.13 lakh<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>13 October 2026 \u00b7 09:35 AM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Dr. Reddy&#x27;s Laboratories (DRREDDY) shares advanced by 2.71% today, trading near the higher end of the day&#x27;s session between \u20b91,224.40 and \u20b91,234.60 after opening at \u20b91,231.10.<\/li>\n<li>The United States Food and Drug Administration completed a pre-approval inspection at the company&#x27;s FTO-11 manufacturing facility located in Pydibhimavaram, Andhra Pradesh, between October 5 and October 7, 2026. The inspection concluded with the issuance of a Form 483 containing two observations, which the company stated it will address within the stipulated timeline.<\/li>\n<li>Trading volume was 0.05 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Why is Dr. Reddy S Laboratories share price rising on 13 October 2026?<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Dr. Reddy&#x27;s Laboratories (DRREDDY) shares advanced by 2.71% today, trading near the higher end of the day&#x27;s session between \u20b91,224.40 and \u20b91,234.60 after opening at \u20b91,231.10.<\/p>\n<p class=\"wt-copy\">The broader market showed positive momentum as the Nifty benchmark rose 0.56%, while the Nifty Pharma sector index declined by 0.45%, highlighting a stock-specific outperformance by Dr. Reddy&#x27;s relative to its sectoral peers. Over a broader timeframe, the stock has posted gains of 2.19% over the past 5 trading days and 7.56% over the past 20 trading days.<\/p>\n<p class=\"wt-copy\">In recent company updates, Dr. Reddy&#x27;s announced that the USFDA completed a pre-approval inspection at its FTO-11 manufacturing facility in Pydibhimavaram, Andhra Pradesh, issuing a Form 483 with two observations. Additionally, the company has scheduled its Q2FY27 financial results announcement and earnings call for October 23, 2026, alongside ongoing preparations for its exclusive distribution partnership for the Qdenga dengue vaccine.<\/p>\n<p class=\"wt-copy\">1.13 lakh shares traded by 13 October 2026 \u00b7 09:35 AM IST. This compares with a 20-day average daily volume of 23.35 lakh shares (0.05 times). The five-day average daily volume was 20.52 lakh shares. Separately, the NSE report for 12 October 2026 showed 8.05 lakh shares delivered, representing 45.84% of that day\u2019s traded volume. The same report recorded 62,826 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>Stock-specific buying amid ongoing positive momentum<\/strong><\/p>\n<p class=\"wt-copy\">The move appears largely stock-specific and consistent with recent positive price momentum over the past 20 trading days, outperforming the broader pharmaceutical sector despite volume running near recent averages.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">USFDA Inspection at Pydibhimavaram Facility<\/div>\n<div class=\"wt-card-date\">8 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The United States Food and Drug Administration completed a pre-approval inspection at the company&#x27;s FTO-11 manufacturing facility located in Pydibhimavaram, Andhra Pradesh, between October 5 and October 7, 2026. The inspection concluded with the issuance of a Form 483 containing two observations, which the company stated it will address within the stipulated timeline.<\/p>\n<p class=\"wt-copy\">Regulatory inspections and observations at key manufacturing sites are vital for maintaining compliance and securing product approvals in regulated markets.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/DRREDDY_08102026155720_SE_intimation_08102026_signed.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Q2FY27 Earnings Call Intimation<\/div>\n<div class=\"wt-card-date\">7 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Dr. Reddy&#x27;s Laboratories announced that it will release its financial results for the quarter and six months ended September 30, 2026, on Friday, October 23, 2026, following a board meeting. Management is also scheduled to host an earnings call at 19:30 PM IST on the same day to discuss financial and operational performance.<\/p>\n<p class=\"wt-copy\">Upcoming earnings disclosures provide critical visibility into revenue growth, margin trends, and management outlook for investors.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/DRREDDY_07102026144117_SE_Intimation_Earning_call_Notification_07102026_signed.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Subsidiary IRS Penalty Disclosure<\/div>\n<div class=\"wt-card-date\">3 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The company disclosed that its step-down wholly owned subsidiary, Dr. Reddy&#x27;s Laboratories, Inc., received a final transcript from the US Internal Revenue Service classifying an amount of $32,350.20 as a penalty. The penalty arose due to a misclassification of the fiscal year reference at the time of tax payment.<\/p>\n<p class=\"wt-copy\">The quantifiable penalty is relatively minor and evaluated by management as having no material impact on the financials or operations of the company.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/DRREDDY_03102026171508_SE_intimation_03102026_signed.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Earnings \/ operating update<\/div>\n<div class=\"wt-card-date\">7 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated October 07, 2026, titled &quot;Intimation of Earnings call&quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/DRREDDY_07102026144117_SE_Intimation_Earning_call_Notification_07102026_signed.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Order \/ business win<\/div>\n<div class=\"wt-card-date\">3 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">imposition of penalty to Dr. Reddy s Laboratories, Inc. ( DRL Inc ), a step-down wholly owned subsidiary of the Company.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/DRREDDY_03102026171508_SE_intimation_03102026_signed.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 June 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">26.64%<\/div>\n<div class=\"wt-note\">26.63% on 31 March 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">32.07%<\/div>\n<div class=\"wt-note\">33.08% on 31 March 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">63.81%<\/div>\n<div class=\"wt-note\">63.80% on 31 March 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1698407_21072026050510_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"insider\" style=\"background:#edf5ff;border:1px solid #c9dbef;border-left:4px solid #4b7fb8;border-radius:10px\">\n<div class=\"wt-card-title\">Historical Insider Activity<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-insider-row\">\n<div class=\"wt-insider-person\"><strong>Patrick Aghanian<\/strong><span class=\"wt-note\">Insider \/ disclosed person<\/span><\/div>\n<div><span class=\"wt-label\">Transaction<\/span><strong>Buy<\/strong><\/div>\n<div><span class=\"wt-label\">Quantity<\/span><strong>3,675 shares<\/strong><\/div>\n<div><span class=\"wt-label\">Trade date<\/span><strong>26 March 2026<\/strong><\/div>\n<\/div>\n<div class=\"wt-insider-row\">\n<div class=\"wt-insider-person\"><strong>Tricia Wetzel<\/strong><span class=\"wt-note\">Insider \/ disclosed person<\/span><\/div>\n<div><span class=\"wt-label\">Transaction<\/span><strong>Buy<\/strong><\/div>\n<div><span class=\"wt-label\">Quantity<\/span><strong>4,275 shares<\/strong><\/div>\n<div><span class=\"wt-label\">Trade date<\/span><strong>9 December 2025<\/strong><\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">Source: NSE transaction disclosures. These are dated historical transactions.<\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 13.16% on 30 June 2026. This compares with 13.19% on 31 March 2026, a change of -0.03 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 40 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">ICICI PRUDENTIAL VALUE DISCOVERY FUND<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">3.68 crore shares \u00b7 4.41%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">NIPPON LIFE INDIA TRUSTEE LTD-A\/C-NIPPON INDIA NIFTY 50 VALUE 20 INDEX FUND<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">1.57 crore shares \u00b7 1.88%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">PARAG PARIKH FLEXI CAP FUND<\/div>\n<div class=\"wt-card-date\">30 June 2026<\/div>\n<div class=\"wt-card-body\">1.47 crore shares \u00b7 1.76%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1698407_21072026050510_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Release of Q2FY27 financial results and management commentary on October 23, 2026<\/li>\n<li>Company response and remediation timeline regarding the USFDA Form 483 observations at the Pydibhimavaram facility<\/li>\n<li>Delivery volume trends and cash market participation relative to the 20-day average volume<\/li>\n<li>Progress on commercialization preparation for the Qdenga dengue vaccine partnership<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/drreddy-share-price-today-2026-10-08\/\">Dr. Reddy&#x27;s Laboratories in Focus After Setting Q2FY27 Earnings Date | 8 October 2026 \u2014 8 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/drreddy-share-price-today-2026-10-07\/\">Dr. Reddy S Laboratories Share Price Today: Why DRREDDY Is Falling 0.35% | 7 October 2026 \u2014 7 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/drreddy-share-price-today-2026-10-05\/\">Dr. Reddy&#x27;s Shares Dip 0.27% Amid Pharma Sector Consolidation | 5 October 2026 \u2014 5 October 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/drreddy\/\">More Dr. Reddy S Laboratories news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Dr. Reddy S Laboratories company news?<\/h3>\n<p class=\"wt-copy\">The United States Food and Drug Administration completed a pre-approval inspection at the company&#x27;s FTO-11 manufacturing facility located in Pydibhimavaram, Andhra Pradesh, between October 5 and October 7, 2026. The inspection concluded with the issuance of a Form 483 containing two observations, which the company stated it will address within the stipulated timeline.<\/p>\n<h3>How strong was Dr. Reddy S Laboratories\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">1.13 lakh shares traded, 0.05 times the 20-day average daily volume. The price and volume data are dated 13 October 2026 \u00b7 09:35 AM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/drreddy-share-price-today-2026-10-13\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/drreddy-share-price-today-2026-10-13\/\"}, \"headline\": \"Dr. Reddy S Laboratories Share Price Today: Why DRREDDY Is Rising 2.71% | 13 October 2026\", \"description\": \"Dr. Reddy S Laboratories share price rose 2.71% to \u20b91,229.40 today. See why DRREDDY is rising, volume context, company developments and what to watch next.\", \"datePublished\": \"2026-10-13T10:47:29.585764+05:30\", \"dateModified\": \"2026-10-13T10:47:29.585764+05:30\", \"author\": {\"@type\": \"Organization\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"reviewedBy\": {\"@type\": \"Person\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"publisher\": {\"@type\": \"Organization\", \"name\": \"WittyTrades\", \"url\": \"https:\/\/www.wittytrades.com\/\"}, \"inLanguage\": \"en-IN\", \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/drreddy-company-news-2026-10-13.jpg\"]}<\/script><!-- wt-article-record:{\"recent_news\":[{\"summary\":\"a press release dated October 07, 2026, titled \\\"Intimation of Earnings call\\\".\",\"category\":\"Press Release\",\"date\":\"07-Oct-2026 14:41:26\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/DRREDDY_07102026144117_SE_Intimation_Earning_call_Notification_07102026_signed.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"imposition of penalty to Dr. Reddy s Laboratories, Inc. ( DRL Inc ), a step-down wholly owned subsidiary of the Company.\",\"category\":\"Action(s) taken or orders passed\",\"date\":\"03-Oct-2026 17:15:38\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/DRREDDY_03102026171508_SE_intimation_03102026_signed.pdf\",\"headline\":\"Order \/ business win\",\"impact\":\"A material order can improve revenue visibility and capacity utilisation. The eventual earnings impact depends on execution timelines and project margins.\",\"importance_score\":5,\"completeness_score\":5},{\"summary\":\"The exchange sought clarification from the company regarding a recent media report. Such a request is a verification step and does not by itself confirm the reported issue.\",\"category\":\"News Verification\",\"date\":\"18-Sep-2026 08:46:20\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/DRREDDY_18092026084516_SE_intimation_18092026_NSE_signed.pdf\",\"headline\":\"Exchange clarification on media report\",\"impact\":\"This can influence near-term sentiment while investors wait for the company's response, but it becomes materially important only if the company confirms a financial or operational impact.\",\"importance_score\":4,\"completeness_score\":3},{\"summary\":\"Dr. Reddy's Laboratories Limited has today, i.e., September 18, 2026, entered into an exclusive distribution and marketing agreement with Takeda Biopharmaceuticals India Private Limited for Qdenga\u00ae in the private market in India.\",\"category\":\"Arrangements for strategic, technical, manufacturing, or marketing tie up\",\"date\":\"18-Sep-2026 09:04:41\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/DRREDDY_18092026090427_DRL_SE_intimation_18092026_signed.pdf\",\"headline\":\"Company update\",\"impact\":\"This is a recent company development worth monitoring. It should not automatically be treated as the sole cause of today's price move.\",\"importance_score\":2,\"completeness_score\":4}],\"insider_activity\":[{\"person\":\"Patrick Aghanian\",\"category\":\"Insider \/ disclosed person\",\"type\":\"Buy\",\"quantity\":\"3675\",\"post_holding\":\"8450\",\"date\":\"26-Mar-2026\",\"mode\":\"ESOP\",\"source\":\"NSE PIT disclosure\"},{\"person\":\"Tricia Wetzel\",\"category\":\"Insider \/ disclosed person\",\"type\":\"Buy\",\"quantity\":\"4275\",\"post_holding\":\"4275\",\"date\":\"09-Dec-2025\",\"mode\":\"ESOP\",\"source\":\"NSE PIT disclosure\"}],\"shareholding_snapshot\":{\"promoter_pct\":26.64,\"public_pct\":73.16,\"fii_pct\":32.07,\"dii_pct\":31.74,\"mf_pct\":13.16,\"institutional_pct\":63.81,\"noninst_pct\":9.35,\"mf_scheme_count\":40,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"ICICI PRUDENTIAL VALUE DISCOVERY FUND\",\"shares\":36842838,\"pct\":4.41},{\"name\":\"NIPPON LIFE INDIA TRUSTEE LTD-A\/C-NIPPON INDIA NIFTY 50 VALUE 20 INDEX FUND\",\"shares\":15682948,\"pct\":1.88},{\"name\":\"PARAG PARIKH FLEXI CAP FUND\",\"shares\":14706891,\"pct\":1.76},{\"name\":\"SBI NIFTY INDEX FUND\",\"shares\":11960032,\"pct\":1.43}],\"period\":\"30-JUN-2026\",\"submission_date\":\"21-JUL-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1698407_21072026050510_WEB.xml\",\"previous_period\":\"31-MAR-2026\",\"previous_promoter_pct\":26.63,\"previous_fii_pct\":33.08,\"previous_dii_pct\":30.72,\"previous_mf_pct\":13.19,\"previous_institutional_pct\":63.8,\"previous_mf_scheme_count\":45,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null}} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dr. Reddy S Laboratories share price rose 2.71% to \u20b91,229.40 today. See why DRREDDY is rising, volume context, company developments and what to watch next.<\/p>\n","protected":false},"author":1,"featured_media":5652,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Dr. Reddy S Laboratories Share Price Today: Why DRREDDY Is Rising 2.71% | 13 October 2026","_witty_meta_description":"Dr. Reddy S Laboratories share price rose 2.71% to \u20b91,229.40 today. See why DRREDDY is rising, volume context, company developments and what to watch next.","_witty_primary_phrase":"Dr. Reddy S Laboratories share price today","_witty_reason_label":"Stock-specific buying amid ongoing positive momentum","_witty_reason_confidence":"low","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[87],"class_list":["post-5653","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-drreddy"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/5653","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=5653"}],"version-history":[{"count":1,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/5653\/revisions"}],"predecessor-version":[{"id":5654,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/5653\/revisions\/5654"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/5652"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=5653"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=5653"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=5653"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}